# TRABD2A

## Overview
The TRABD2A gene encodes the protein TraB domain containing 2A, which is categorized as a membrane metalloprotease. This protein plays a crucial role in various cellular processes, including protein degradation and signaling pathways, and is particularly noted for its Wnt-protein binding and metalloendopeptidase activities. These functions suggest its involvement in modulating cellular functions and contributing to organismal development and homeostasis (Tantawy2023WholeExome). TRABD2A is also implicated in cardiovascular health, with genetic variants near the gene linked to elevated cardiac troponin T levels and increased expression in heart tissue, indicating its potential role in heart function (Tantawy2023WholeExome). Additionally, TRABD2A has been identified as a host restriction factor against HIV-1, where it limits viral production by degrading the Gag polyprotein in resting CD4+ T cells, highlighting its significance in antiviral defense mechanisms (Liang2019Membrane).

## Structure


## Function
The TRABD2A gene encodes a protein involved in several cellular processes, including protein degradation and signaling pathways. This protein is known for its Wnt-protein binding activity and metalloendopeptidase activity, which suggests a role in modulating cellular functions and contributing to organismal development and homeostasis (Tantawy2023WholeExome). In the context of cardiovascular health, TRABD2A is associated with the regulation of cardiac function. Genetic variants near the TRABD2A gene have been linked to elevated cardiac troponin T levels, which are indicators of cardiovascular diseases and heart failure. These variants are also associated with higher expression of TRABD2A in left ventricle heart tissue, indicating its potential involvement in heart function (Tantawy2023WholeExome).

In addition to its role in cardiovascular health, TRABD2A has been identified as a membrane metalloprotease that restricts HIV-1 production by degrading the viral Gag polyprotein in resting CD4+ T cells. This activity highlights its function in antiviral defense mechanisms, suggesting that TRABD2A could be a target for therapeutic interventions against HIV-1 (Liang2019Membrane). The protein is typically active in the cytoplasm, where it interacts with other proteins to regulate cell growth and differentiation.

## Clinical Significance
Mutations and altered expression of the TRABD2A gene have been linked to various clinical conditions. In the context of multiple myeloma, genetic variants at the TMSB10/TRABD2A locus have been associated with an increased risk of carfilzomib-related cardiotoxicity. Specifically, the missense SNP rs7148 in the TMSB10 gene, which is in linkage disequilibrium with an intronic variant rs12471929, has been shown to correlate with higher cardiovascular adverse events in patients treated with carfilzomib, a proteasome inhibitor. This association is significant, with an odds ratio of 9.33, indicating a strong genetic predisposition to cardiotoxicity in affected individuals (Tantawy2023WholeExome).

The TRABD2A gene is also involved in the regulation of cardiac troponin T levels, which are markers for cardiovascular diseases and heart failure. Variants near TRABD2A have been identified in genome-wide association studies as being linked to elevated levels of this cardiac biomarker, suggesting a broader role in cardiovascular health (Tantawy2023WholeExome).

In addition to its role in cardiovascular conditions, TRABD2A has been identified as a host restriction factor against HIV-1, inhibiting viral assembly and production by degrading the HIV-1 Gag protein. This function highlights its potential as a therapeutic target in antiviral strategies (Liang2019Membrane; Liu2019Metalloprotease).

## Interactions
TRABD2A, a protein encoded by the TRABD2A gene, is involved in restricting HIV-1 production by degrading the viral Gag polyprotein, thereby limiting the production of HIV-1 progeny in resting CD4+ T cells. This activity suggests that TRABD2A interacts with viral components, specifically the Gag polyprotein, to exert its antiviral effects (Liang2019Membrane). The study also indicates that TRABD2A's antiviral function can be modulated by specific antibodies and metal ions, which implies potential interactions with these molecules that could influence its activity (Liang2019Membrane).

The research further explores the interactions of TRABD2A with viral components using techniques such as flow cytometry and immunofluorescence, which demonstrate its impact on the Gag and Env proteins of the virus. These findings highlight the protein's role in the degradation of viral proteins, suggesting a direct interaction with these viral elements (Liang2019Membrane). While the specific partners and mechanisms of TRABD2A's interactions require further investigation, its ability to modulate HIV-1 production through interactions with viral proteins positions it as a potential target for therapeutic intervention against HIV-1 (Liang2019Membrane).


## References


[1. (Tantawy2023WholeExome) Marwa Tantawy, Guang Yang, Raghunandan Reddy Algubelli, Gabriel DeAvila, Samuel M. Rubinstein, Robert F. Cornell, Michael G. Fradley, Erin M. Siegel, Oliver A. Hampton, Ariosto S. Silva, Daniel Lenihan, Kenneth H. Shain, Rachid C. Baz, and Yan Gong. Whole-exome sequencing analysis identified tmsb10/trabd2a locus to be associated with carfilzomib-related cardiotoxicity among patients with multiple myeloma. Frontiers in Cardiovascular Medicine, June 2023. URL: http://dx.doi.org/10.3389/fcvm.2023.1181806, doi:10.3389/fcvm.2023.1181806. This article has 2 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fcvm.2023.1181806)

[2. (Liang2019Membrane) Guoxin Liang, Li Zhao, Ying Qiao, Wenqing Geng, Xiaowei Zhang, Mei Liu, Jinxiu Dong, Haibo Ding, Hong Sun, and Hong Shang. Membrane metalloprotease trabd2a restricts hiv-1 progeny production in resting cd4+ t cells by degrading viral gag polyprotein. Nature Immunology, 20(6):711–723, May 2019. URL: http://dx.doi.org/10.1038/s41590-019-0385-2, doi:10.1038/s41590-019-0385-2. This article has 18 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/s41590-019-0385-2)

[3. (Liu2019Metalloprotease) Mei Liu, Jinxiu Dong, Jiayue Ouyang, Li Zhao, Guoxin Liang, and Hong Shang. Metalloprotease trabd2a restriction of hiv-1 production in monocyte-derived dendritic cells. AIDS Research and Human Retroviruses, 35(10):887–889, October 2019. URL: http://dx.doi.org/10.1089/aid.2019.0140, doi:10.1089/aid.2019.0140. This article has 3 citations and is from a peer-reviewed journal.](https://doi.org/10.1089/aid.2019.0140)